DNA Methylation Analysis in Population Genetics: When to Use Methylation Arrays

For Research Use Only. Not for use in diagnostic procedures or clinical decision-making.

DNA methylation is the most measured epigenetic mark in population cohorts — but choosing how to measure it is not straightforward. Whole-genome bisulfite sequencing (WGBS) captures upwards of 95% of the ~28 million CpG sites in the human genome. Methylation arrays capture roughly 3% of them. On coverage alone, sequencing appears to be the obvious winner. But for population-scale studies where reproducibility, cost, and statistical power determine what can be discovered, arrays have remained the workhorse for over a decade — and the newest generation of arrays deepens that advantage for most cohort designs.

This guide explains when methylation arrays are the right tool, when they are not, and how to design an EWAS that produces replicable findings rather than cell-type artifacts. It is written for epigenetics researchers, cohort study teams, and population genetics groups evaluating methylation profiling platforms for studies ranging from a few hundred to tens of thousands of samples.

Figure 1: The DNA methylation profiling platform landscape spans targeted arrays (MSA 270K), comprehensive arrays (EPIC v1.0/v2.0 850K–935K), and sequencing-based methods (WGBS, RRBS, EM-seq) — each occupying a distinct position in the trade-off between per-sample cost, CpG coverage, and reproducibility at scale.

The Methylation Array Landscape

Three generations of Illumina Infinium methylation arrays define the current platform landscape:

• HumanMethylation450K (450K): Released 2011, covers ~485,000 CpG sites with emphasis on gene promoters, CpG islands, and coding regions. Still present in many legacy cohort datasets and meta-analyses, but no longer manufactured.
• MethylationEPIC v1.0 (850K): Released 2015, expanded coverage to ~865,000 CpG sites including enhancer regions, FANTOM5 promoters, and ENCODE regulatory elements. The most widely used platform in published EWAS to date.
• MethylationEPIC v2.0 (935K): Released 2022, covers >935,000 CpG sites with further enhancer and regulatory element expansion. Peters et al. (2024) demonstrated high reproducibility with EPIC v1.0 and validated cross-platform concordance against WGBS. Cross-hybridizing probes remain a concern — approximately 8–10% of probes show off-target binding — and should be filtered during preprocessing.
• Methylation Screening Array (MSA, 270K): A cost-optimized array covering ~270,000 CpG sites selected from 1,067 published EWAS studies across 16 disease phenotypes. On average, each MSA locus is associated with 5.6 phenotypes — roughly 2.5× higher than the per-probe phenotype density of EPIC v2.0. Suitable for very large cohorts where comprehensive coverage is traded for sample throughput at approximately one-third the cost per sample.

For research teams planning population-scale methylation studies, DNA methylation microarray for population genetics provides end-to-end services from bisulfite conversion and array processing through bioinformatic analysis.

Table 1: Comparison of DNA Methylation Profiling Platforms for Population Studies

Note: Prices are approximate estimates for comparison; actual costs may vary. Please check with vendors for current quotes.

When Arrays Beat Sequencing

For population studies that need to measure methylation across hundreds or thousands of samples, arrays have three structural advantages that WGBS cannot match at current costs.

Reproducibility at Scale

Methylation arrays measure a fixed set of CpG sites with precision equivalent to approximately 100× sequencing depth. Every sample is assayed at exactly the same CpG positions using the same probe chemistry. WGBS coverage, by contrast, is stochastic — the set of CpGs covered at sufficient depth varies from sample to sample, and sites covered in one sample may be absent in another. For longitudinal studies that need to measure the same CpG across time points, or meta-analyses that pool data across cohorts, the fixed-content design of arrays is a practical necessity. A 2024 study by Lussier et al. found that epigenetic age estimates were more stable across array versions when using principal-component-based clock formulations, but cross-platform portability remained a challenge even between array generations — WGBS-to-array portability is substantially more difficult.

Cost per Sample vs. Statistical Power

An EPIC v2.0 array costs roughly $200–400 per sample, including bisulfite conversion, hybridization, and scanning. WGBS at 30× coverage costs $1,000 or more per sample. For a study with a $100,000 budget, that difference translates to roughly 300–400 array-processed samples versus fewer than 100 WGBS-processed samples. Given that Mansell et al. (2019) demonstrated that ~1,000 samples are required for adequately powered EWAS, the cost differential makes arrays the only practical option for most population-scale studies.

Established Analytical Ecosystem

More than a decade of array-based EWAS has produced mature preprocessing pipelines (minfi, meffil, ChAMP, ENmix), well-characterized probe filtering criteria (cross-hybridizing probes, SNP-affected probes, low-reliability probes), validated cell type deconvolution references (Houseman method, FlowSorted.Blood.EPIC), and consortia-grade meta-analysis frameworks (PACE, GoDMC). Choosing arrays means entering a well-mapped analytical territory; choosing WGBS means navigating a landscape where consensus on normalization, coverage filtering, and statistical modeling is still emerging.

Where Arrays Fall Short

Arrays are not the right tool for every methylation question. Understanding their blind spots prevents investing in a study design that cannot answer the question it was funded to address.

Coverage Gaps in Regulatory Regions

The EPIC v2.0 array covers ~3% of all CpG sites in the human genome. While these sites are enriched for known regulatory elements, they systematically miss intergenic and distal regulatory regions. A 2024 medRxiv study comparing WGBS-based MWAS to array-restricted analyses in monocytes found that full WGBS identified substantially more gene-phenotype associations than either the 450K or EPIC probe set alone. For traits where the causal methylation changes occur in enhancers or other regulatory elements not represented on arrays, array-based EWAS will produce false negatives regardless of sample size.

Multi-Ancestry Populations

Array probe selection was historically biased toward European reference genomes. A 2025 study of population-specific co-methylated regions (CMRs) using WGBS in lymphoblastoid cell lines from European and African ancestry individuals identified 101 population-specific CMRs. Only 15 of these 101 regions were quantifiable by any existing methylation array. This means that ~85% of population-differentiated methylation regions are invisible to arrays. For multi-ancestry cohort studies or studies in populations underrepresented in array design, WGBS or targeted capture sequencing provides essential coverage that arrays cannot.

Methylation Beyond CpG

Arrays measure only CpG methylation at pre-selected sites. They cannot detect non-CpG methylation (CpH), allele-specific methylation at sites not covered by probes, or 5-hydroxymethylcytosine (5hmC) — all of which are accessible via bisulfite or enzymatic sequencing approaches. For studies focused on these marks, arrays are fundamentally the wrong platform.

Designing a Population EWAS

A well-designed population EWAS controls for confounders at the study planning stage. The analysis pipeline matters, but the design decisions made before the first sample reaches the bench matter more.

Sample Size and Power

Mansell et al. (2019) used empirical null simulations from 1,175 samples on the EPIC v1.0 array to establish that approximately 1,000 samples are needed to detect small methylation differences at the majority of array sites with adequate power. The family-wise error rate threshold for the EPIC array was calculated at P < 9 × 10⁻⁸. Studies with fewer than 500 samples should be considered exploratory and are unlikely to produce replicable single-CpG associations unless effect sizes are unusually large. For reference, a 2% methylation difference between groups requires roughly 500 cases and 500 controls for 80% power at most sites.

The Covariate Hierarchy

Confounders in EWAS follow a predictable rank order. Addressing them in this sequence — from largest to smallest effect — maximizes the chance of finding true biological signal:

1. Cell composition (rank 1): Each blood cell type has a distinct methylome. A CpG that is 90% methylated in granulocytes and 10% in lymphocytes will appear differentially methylated in any phenotype that alters the granulocyte-to-lymphocyte ratio — which includes age, inflammation, smoking, and most diseases. The Houseman et al. (2012) reference-based deconvolution method, implemented in the minfi R package, estimates the proportions of six major blood cell types (B cells, CD4+ T cells, CD8+ T cells, granulocytes, monocytes, NK cells) from methylation data. Always include estimated cell proportions as covariates in EWAS models.
2. Batch and array position (rank 2): An EPIC array processes eight samples on a single BeadChip. Samples on the same chip share technical variation; samples in the same plate share batch-level variation. Randomize cases and controls across chips and positions before sample submission. If all cases run on one chip and all controls on another, the study is unrecoverable — phenotype and batch become statistically inseparable.
3. Age and sex (rank 3): Age is the most reproducible methylome correlate. Sex influences X-chromosome methylation and X-inactivation patterns. Always include both as covariates.
4. Smoking and environmental exposures (rank 4): Smoking produces the largest known blood methylation signature. Use a methylation-derived smoking score rather than self-report; the AHRR locus (cg05575921) serves as a positive control for smoking signal detection.
5. Genetic ancestry and mQTL (rank 5): Many CpG sites are under genetic control. Population structure can confound EWAS when ancestry differs between case and control groups. Include genetic principal components as covariates — population structure analysis provides the ancestry inference and PCA framework for this adjustment — and filter SNP-proximal probes that may cross-hybridize with sequence variants rather than measuring true methylation.

Figure 2: Addressing confounders in the correct rank order — starting with cell composition and ending with genetic ancestry — maximizes the chance of finding true biological signal in population EWAS, while randomization of samples to chips and array positions is the single most important pre-analytical design decision.

Inflation Control

van Iterson et al. (2017) demonstrated that EWAS test statistics are routinely both inflated and deflated — a different pattern from GWAS, where inflation is typically uniform. Applying GWAS-style genomic control (dividing all test statistics by lambda) to EWAS can over-correct or under-correct depending on the site. The BACON method (R/Bioconductor) fits a Bayesian mixture model to the empirical null distribution, estimating both bias (mean shift) and inflation (scale) separately. Always report QQ plots before and after correction. If the smoking-associated AHRR probe (cg05575921) is eliminated after correction, the correction is too aggressive.

Methylation in Multi-Omics Integration

DNA methylation sits at the interface of genetic variation and gene expression, making it a natural bridge in multi-omics QTL studies. Methylation quantitative trait loci (mQTLs) — genetic variants that associate with CpG methylation levels — provide the mechanistic link between GWAS variants and downstream molecular phenotypes.

The mQTL-to-Phenotype Path

A typical multi-omics chain involving methylation runs: SNP → methylation change at a CpG site → altered gene expression → phenotypic effect. Colocalization of mQTL and eQTL signals at the same variant strengthens the evidence that methylation mediates the expression effect. Mediation analysis then tests whether the variant's effect on expression goes through methylation (indirect/mediated effect) or acts independently (direct effect, e.g., disrupting a transcription factor binding site without methylation involvement).

For research teams working with methylation array data alongside genotype and phenotype data, multi-omics QTL integration provides the analytical workflow for colocalization and mediation analysis across omics layers.

Platform Considerations for mQTL Studies

mQTL discovery requires adequate coverage of CpG sites across the genome. Because arrays cover only a subset of all CpGs, array-based mQTL catalogs are systematically incomplete — they detect mQTLs only for the ~3% of CpGs represented on the array. For mQTL discovery in populations not of European ancestry, where array probe coverage is weakest, targeted bisulfite sequencing or capture-based approaches (MethylC-capture) can supplement array data for the genomic regions most relevant to the trait of interest.

For projects that combine methylation data with gene expression, genotype, and phenotype information, multi-omics integration services provide the computational infrastructure for colocalization, mediation analysis, and multi-layer evidence scoring. When the phenotype of interest is drug response, pharmacogenomics QTL analysis extends the mQTL framework to identify methylation-mediated pharmacological effects.

Choosing the Right Platform

The platform decision reduces to three questions: How many samples? What populations? What biological questions?

Table 2: Platform Selection Decision Framework

Figure 3: The platform selection decision framework is governed by three questions — sample count, population diversity, and biological question — with arrays preferred for large-N blood-based EWAS, WGBS for discovery and multi-ancestry studies, and hybrid designs increasingly the standard for population epigenetics consortia.

Hybrid Designs

When budget or sample availability constrains the choice between coverage and throughput, a hybrid design mates the strengths of both platforms: sequence a discovery subset (100–300 samples) by WGBS or MethylC-capture to comprehensively map methylation variation, then validate the top-associated CpGs in the full cohort (thousands of samples) using targeted bisulfite pyrosequencing or custom array content. This approach captures discovery power from WGBS while retaining the statistical power of large-N array cohorts, and is increasingly the design of choice in population epigenetics consortia.

Frequently Asked Questions

For Research Use Only. Not for use in diagnostic procedures or clinical decision-making.

  Related Services

Whole Exome Sequencing for Population Genetics

Genetic Diversity Analysis

Genome-wide Association Analysis Service

QTL Location Analysis Service

Whole Genome Re-sequencing for Population Genetics

Selective Sweep Analysis Service

Reduced-Representation Sequencing for Population Genetics

Evolutionary Tree Analysis Service

  Download

Power Your Regulatory Discoveries with DAP-seq: A MYB-GLK Case Study

EM-seq Services for High-Resolution DNA Methylation Analysis

Multi-Omics Strategies to Decode Molecular Mechanisms at Every Level

Explore Customized Bioinformatics Services: Case Studies & Insights